Miruvor
Sign up
The short answer

What studies of vestibular therapy found

2papers on vestibular therapy
1 (few people)person in 1 study testing vestibular therapy alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for daily functioning.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Vestibular therapy might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 2 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Vestibular therapy · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Daily life and health overall

Daily functioning1 study · 1 (few people) person took part in vestibular therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 1 hour after the placement · 5 treatments in 3 days with REMOBI & AIDEAL double step, between 9 and 17 months after the start of symptoms (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of vestibular therapy on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Post-COVID-19 dizziness associated with a patulous eustachian tube. (2025)

    People in the study
    1 in the study
    Dose
    5 treatments in 3 days with REMOBI & AIDEAL double step, between 9 and 17 months after the start of symptoms
    Outcome
    working with computer screens
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue1 study

All papers

  1. Post-COVID-19 dizziness associated with a patulous eustachian tube.2025 · case report · 1 in the study
    Summary

    This case report describes one patient in his 40s with persistent dizziness after SARS-CoV-2 infection. A tympanostomy tube was placed 6 months after the start of symptoms. Patient-reported dizziness resolved immediately, and nystagmus size was reduced from about 0.7°/s to about 0.4°/s at 1 hour after placement. The patient later developed ocular fatigue and pain associated with eye movement, diagnosed as vestibular asthenopia; these symptoms were largely resolved after vestibulo-visual rehabilitation given as 5 treatments in 3 days between 9 and 17 months after the start of symptoms. The ventilation tube spontaneously released after 20 months, accompanied by some bleeding. Outcomes were before-and-after observations in one patient; there was no comparison group. Measurements included patient-reported dizziness, nystagmus, nausea during vestibular tests, eye movement parameters, and work limitations. The authors state they could not ascertain whether the PET was absent before SARS-CoV-2 infection.

  2. Persistent postural perceptual dizziness (PPPD) in pediatric patients after COVID-19 infection.2024 · case report · 9 in the study · 8 started · 8 with outcome data
    Summary

    This case series describes 9 adolescent patients with long-COVID and persistent postural-perceptual dizziness (PPPD) referred from a multidisciplinary long-COVID clinic to a pediatric vestibular clinic. Recommended treatment for all PPPD patients included vestibular physical therapy (PT), cognitive behavioral therapy (CBT), and a selective serotonin reuptake inhibitor (SSRI). Eight of 9 agreed to follow-up; follow-up ranged from 1 to 21 months (average: 8.8 months). All 8 patients underwent vestibular PT, attending an average of 27.4 (range: 11–60) sessions over an average of 4.9 (range: 1.5–8) months. 7/8 also underwent CBT with an average of 27 (range: 6–67) sessions, and 5/8 took an SSRI for an average of 7.8 (range: 1–13) months. The paper reports no comparison group. Outcomes included the DHI-pc, the Niigata PPPD questionnaire, and patient-reported percentage change. The average estimated percentage improvement in overall symptoms was 63 % (range 0–100 %), and in activity level was 73 % (range 10–100 %). DHI-pc scores improved in all patients by 18 points on average (range: 2–54; p = 0.017), and the percentage improvement in DHI-pc score was 35 % on average. The average post-treatment Niigata PPPD score was 18.5 (range: 0–50). Dizziness improved in 75 % of patients and remained stable in 25 %. At follow-up all patients attended school 5 days a week, ranging from 3 to 6.5 (average: 4.5) hours per day. None of the patients experienced new symptoms at follow-up; all but 2 experienced set-backs during follow-up. The paper does not report withdrawals, and no withdrawal is described in connection with harms. Authors state limits including selection bias.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime